When: Confirmed close $212-215 on >25M volume

Then: Death cross resolution add

When: Golden cross + close above $215

Then: Upgrade to Buy

When: Break below $173 close OR forward EPS cut below $14.50

Then: Downgrade recommendation

WAIT: Do not initiate at $195.05. Wait for confirmation (close above $205 on 8M+ volume, capitulation flush to $185-190, or 2-3 week basing above $200 flattening the 200-day MA). Only then enter with the aggressive trader's $173 stop and 2% sizing.

• Stock collapsed from $282 in January to ~$126 in June — cause unspecified, making 12x earnings on a 'damaged business' not equivalent to 12x on healthy one
• October 1st saw 28.98M share print (~4.7% of 612M float) followed by reversal from $227.63 to $198.90 close — institutional distribution pattern regardless of narrative
• VWMA sits at $194.21 with stock at ~$194.21 — thin $1 cushion above a technical tripwire
• 200-day MA at $193; a pullback to $180 that breaks it is not a buying opportunity but a trend failure confirmation
• 10.3% shareholder yield: 3.28% dividend is contractual, but 7% buyback yield is discretionary — cutable overnight by board vote during downturns
• Goodwill stands at $25.3B against stockholders' equity of $31.9B (79% of book value); a 10% writedown = $2.5B, ~30% of TTM net income — does not require recession, only acquisition underperformance
• Revenue growth decelerated from double digits to ~5.6%; $923M in restructuring charges across two quarters are impairment signals already on the tape
• Macro environment: divided Fed with rising dissent, softening labor market, 'hollow tree' warning from leading bond investor, market hitting highs on narrowing breadth — textbook 10-15% drawdown environment with ACN beta of 1.10
• Zero institutional news flow and zero retail discussion for 7 days on a $119B market cap stock is unusual and concerning post-Q4 late September
• May 2026 EPS of $3.80 compared against Q4 FY25 EPS of $2.25 (deliberately impaired by $615M restructuring charge) is normalization off a low denominator, not structural breakout
• Forward EPS consensus of $15.95 implies ~$3.99/quarter average — barely above where just printed, so recovery is already priced in per consensus
• $173 stop (7% below $195) does not protect against gap-down opens on macro news; Polymarket 8% recession probability can reprice in days
• A 22bp loss on low-quality entries repeated across names is how portfolios bleed — small size does not justify poor entry quality

→ vs aggressive: 3-to-1 setup anchoring upside to $240-260 (pre-collapse range) without identifying what caused the structural dislocation from $282 to $126

→ vs aggressive: October 1st gap-up as 'short squeeze' narrative ignores 28.98M share institutional distribution print reversing from $227.63 to $198.90, with two-day continuation to $195.05

→ vs aggressive: Staged adds at $178-182 treating 50-day MA pullback as free optionality — but a pullback that breaks the reclaimed 200-day at $193 is a trend failure, not a buying signal

→ vs aggressive: 10.3% shareholder yield centerpiece: 7% buyback component is discretionary and cuttable; calling it a 'guaranteed cushion' is misleading

→ vs aggressive: Bear case dismissed as requiring 'triple tail' — but 10% goodwill writedown ($2.5B) is 30% of TTM net income and does not require recession, only acquisition underperformance

→ vs aggressive: Soft landing assumed sustainable; Polymarket 8% recession probability can reprice in days on bad unemployment/JOLTS/tech guidance data

→ vs aggressive: Zero news flow for 7 days post-Q4 late September is unusual; suggests either non-event print (no catalyst) or negative print the market moved on from without commentary

→ vs aggressive: $3.80 May 2026 EPS celebrated as 'highest in five quarters' — but comparing to Q4 FY25's deliberately impaired $2.25 EPS is a low-denominator trick, not recovery

→ vs aggressive: Forward EPS of $15.95 implies ~$3.99/quarter, barely above the impaired print — recovery is already priced in per consensus estimates

→ vs aggressive: $173 stop does not protect against macro gap-down opens; betas 1.10 means ACN underperforms on broad market drawdowns

MODIFIED BUY: 1% starter, defined entry triggers ($200 close on 7M+ volume OR $187-191 flush with capitulation), stop at $1.73 (trail to $1.91 at +$10 profit), add to 1.5% on first confirmation, cap at 2.5% total.

• Valuation: 12x forward earnings for 26% ROE business; stock fell 55% from January to June indicating market is still 'punishing' the underlying business
• May 2026 EPS $3.80 is normalization, not breakout, and highest in five quarters; forward earnings of $15.95 implies ~5% sequential growth
• Dividend yield of 3.28% with $5B net cash and $16B annual FCF makes entry defensible even if buybacks suspend
• Goodwill at $25B against $32B equity is disclosed and already priced into 12x multiple; cannot argue both that multiple is too high AND too low on goodwill
• Zero institutional news likely reflects Q4 FY26 digest period with next catalyst Q1 FY27 print in late December; 3-month quiet window ahead
• Entry quality is poor: declining 200-day moving average, failed gap up above, VWMA tripwire at $1.94
• Conservative's waiting triggers (close above $205, flush to $185, 2-3 week basing) are three different scenarios with no defined timeline
• Trade is not a growth story; it is a quality compounder at a depressed multiple requiring correct framing and sizing

→ vs aggressive: Multiples do not mean revert on a clock; the 55% decline is a market signal that cannot be ignored; technical picture is neutral at best, not supportive; 2% position size 'trivializes' risk across multiple names

→ vs conservative: Waiting has real 33% opportunity cost (23% price + 10% capital return); no upper time limit or defined catalyst in waiting framework; overstating buyback suspension risk given $16B FCF and $5B net cash; using goodwill as reason to avoid trade while claiming multiple is too high is inconsistent